RBRobert E. Bristow

Robert E. Bristow

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert E. Bristow has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes

    by Robert E. Bristow, Marianna L. Zahurak, Teresa P. Diaz-Montes, Robert L. Giuntoli, Deborah K. Armstrong


  • Analysis of Contemporary Trends in Access to High-Volume Ovarian Cancer Surgical Care

    by Robert E. Bristow, Isha Puri, Teresa P. Diaz-Montes, Robert L. Giuntoli, Deborah K. Armstrong

    Positive volume-outcome relationships exist for cancers treated with technically complex surgery, including ovarian cancer. However, contemporary patterns of primary surgical care for ovarian cancer according to hospital and surgeon case volume remain poorly defined. The Maryland Health Service Cost Review Commission database was accessed for annual hospital and surgeon primary ovarian cancer surgical case volume for 2001–2008 and evaluated for statistically significant trends in access to high-volume surgical care compared with the earlier period for 1990–2000. χ2 and logistic regression analyses were used to evaluate for significant trends in case volume distribution over time as well as factors associated with access to high-volume care. Overall, 2,475 primary ovarian cancer operations were performed by 472 surgeons at 43 hospitals. There was a statistically significant increase in the proportion of cases performed at high-volume centers from 22.8% in 1990–2000 to 61.1% in 2001–2008 (odds ratio = 5.30, 95% confidence interval = 4.68–6.00, P < .0001), while low-volume hospital case distribution decreased from 49.6 to 31.3%. Access to high-volume surgeons increased from 34.5% in 1990–2000 to 64.5% in 2001–2008 (odds ratio = 3.44, 95% confidence interval = 3.06–3.87, P < .0001), while the proportion of cases performed by low-volume surgeons decreased from 56.3 to 28.9%. After controlling for other variables, high-volume surgeons were significantly more likely to perform ovarian cancer surgery that included hysterectomy and staging/cytoreductive surgical procedures. The proportions of ovarian cancer patients undergoing primary surgery at high volume centers and by high-volume surgeons increased statistically significantly from 1990–2000 to 2001–2008. Further investigation is necessary to determine factors contributing to this favorable trend.


  • Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: Operative technique and clinical outcome

    by Robert E. Bristow, Michele Peiretti, Melissa Gerardi, Vanna Zanagnolo, Stefanie Ueda, Teresa Diaz-Montes, Robert L. Giuntoli, Angelo Maggioni


  • Open Access

    Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer

    by Jianghong Li, Cheryl A Sherman-Baust, Miyun Tsai-Turton, Robert E Bristow, Richard B Roden, Patrice J Morin

    Background: The absence of highly sensitive and specific serum biomarkers makes mass screening for ovarian cancer impossible. The claudin proteins are frequently overexpressed in ovarian cancers, but their potential as prognostic, diagnostic, or detection markers remains unclear. Here, we have explored the possible use of these proteins as screening biomarkers for ovarian cancer detection. Methods: Claudin protein shedding from cells was examined by immunoblotting of conditioned culture media. The presence of claudins in exosomes released from ovarian cancer cells was demonstrated by sucrose gradient separation and immunogold electron microscopy experiments. Claudin-4-containing exosomes in the plasma of ovarian cancer patients were evaluated in a pilot panel of 63 ovarian cancer patients and 50 healthy volunteers. The CA125 marker was also assessed in these samples and compared with claudin-4 positivity. Results: We show that full-length claudins can be shed from ovarian cancer cells in culture and found in the media as part of small lipid vesicles known as exosomes. Moreover, 32 of 63 plasma samples from ovarian cancer patients exhibited the presence of claudin-4-containing exosomes. In contrast, only one of 50 samples from individuals without cancer exhibited claudin-4-positive exosomes. In our small panel, at a specificity of 98%, the claudin-4 and CA125 tests had sensitivities of 51% and 71%, respectively. The two tests did not appear to be independent and were strongly correlated. Conclusion: Our work shows for the first time that claudin-4 can be released from ovarian cancer cells and can be detected in the peripheral circulation of ovarian cancer patients. The development of sensitive assays for the detection of claudin-4 in blood will be crucial in determining whether this approach can be useful, alone or in combination with other screening methods, for the detection of ovarian cancer.


  • Transverse colectomy in ovarian cancer surgical cytoreduction: Operative technique and clinical outcome

    by Robert E. Bristow, Michele Peiretti, Vanna Zanagnolo, Ritu Salani, Robert L. Giuntoli, Angelo Maggioni